« BackRadiotherapy & Oncology
Article in Press

Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of dosimetric and clinical factors

  • Ivo Beetz

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, University Medical Center Groningen, P.O. Box 30001, 9300 RB Groningen, The Netherlands.
  • ,
  • Cornelis Schilstra

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Fred R. Burlage

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Phil W. Koken

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center (VUMC), Amsterdam, the Netherlands
  • ,
  • Patricia Doornaert

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center (VUMC), Amsterdam, the Netherlands
  • ,
  • Henk P. Bijl

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Olga Chouvalova

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • C. René Leemans

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands
  • ,
  • Geertruida H. de Bock

      Affiliations

    • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Miranda E.M.C. Christianen

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Bernard F.A.M. van der Laan

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Arjan Vissink

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • ,
  • Roel J.H.M. Steenbakkers

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • ,
  • Johannes A. Langendijk

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Received 8 October 2010; received in revised form 28 March 2011; accepted 3 May 2011. published online 01 June 2011.
Corrected Proof

Abstract 

Purpose

The purpose of this multicentre prospective study was to investigate the significance of the radiation dose in the major and minor salivary glands, and other pre-treatment and treatment factors, with regard to the development of patient-rated xerostomia and sticky saliva among head and neck cancer (HNC) patients treated with primary (chemo-) radiotherapy ((CH)RT).

Methods and materials

The study population was composed of 167 consecutive HNC patients treated with three-dimensional conformal (3D-CRT) (CH) RT. The primary endpoint was moderate to severe xerostomia (XER6m) as assessed by the EORTC QLQ-H&N35 at 6months after completing (CH)RT. The secondary endpoint was moderate to severe sticky saliva at 6months (STIC6m). All organs at risk (OARs) potentially involved in salivary function were delineated on planning-CT, including the parotid, submandibular and sublingual glands and the minor glands in the soft palate, cheeks and lips. Patients with moderate to severe xerostomia or sticky saliva at baseline were excluded. The optimum number of variables for a multivariate logistic regression model was determined using a bootstrapping method.

Results

The multivariate analysis showed the mean parotid dose, age and baseline xerostomia (none versus a bit) to be the most important predictors for XER6m. The risk of developing xerostomia increased with age and was higher when minor baseline xerostomia was present in comparison with patients without any xerostomia complaints at baseline. Model performance was good with an area under the curve (AUC) of 0.82.

For STIC6m, the mean submandibular dose, age, the mean sublingual dose and baseline sticky saliva (none versus a bit) were most predictive for sticky saliva. The risk of developing STIC6m increased with age and was higher when minor baseline sticky saliva was present in comparison with patients without any sticky saliva complaints at baseline. Model performance was good with an AUC of 0.84.

Conclusions

Dose distributions in the minor salivary glands in patients receiving 3D-CRT have limited significance with regard to patient-rated symptoms related to salivary dysfunction. Besides the parotid and submandibular glands, only the sublingual glands were significantly associated with sticky saliva. In addition, reliable risk estimation also requires information from other factors such as age and baseline subjective scores. When these selected factors are included in predictive models, instead of only dose volume histogram parameters, model performance can be improved significantly.

Keywords: Radiotherapy, Xerostomia, Head and neck cancer, Normal tissue complication probability models, Nomograms

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(11)00202-7

doi:10.1016/j.radonc.2011.05.010

« BackRadiotherapy & Oncology